Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/17
A61K-039/395
C07K-014/705
C07K-014/435
출원번호
US-0638834
(2000-08-14)
등록번호
US-7396810
(2008-07-08)
발명자
/ 주소
Clinton,Gail M.
출원인 / 주소
Oregon Health Sciences University
대리인 / 주소
Davison,Barry L.
인용정보
피인용 횟수 :
3인용 특허 :
42
초록▼
An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in
An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8 fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interfered with EGF activation of the EGF receptor in cotransfected cells demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression. For both p185HER-2 and the EGF receptor, the extent of inhibition was affected by the expression levels of herstatin relative to the receptor. Herstatin is an autoinhibitor of p185HER-2 and expands its inhibitory activity to another member of the group I family of receptor tyrosine kinases, the EGF receptor.
대표청구항▼
We claim: 1. A method for treating a solid tumor characterized by expression of EGF receptor, comprising administering, to a subject in need thereof determined to have a tumor expressing the EGF receptor, an agent that binds to the extracellular domain of EGF receptor, wherein the agent is selected
We claim: 1. A method for treating a solid tumor characterized by expression of EGF receptor, comprising administering, to a subject in need thereof determined to have a tumor expressing the EGF receptor, an agent that binds to the extracellular domain of EGF receptor, wherein the agent is selected from the group consisting of (a) an isolated polypeptide comprising the amino acid sequence of SEQ ID NOS:11, 15 or 17-26, or fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1, (b) an isolated and glycosylated polypeptide comprising the amino acid sequence of SEQ ID NOS:12, 38 or 27-36, or fragments thereof of about 80 to 419 contiguous residues in length, wherein the C-terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, and wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1, (c) a monoclonal antibody that binds to the extracellular domain of EGF receptor, and (d) combinations thereof, with the proviso that where the composition comprises the monoclonal antibody it also comprises at least one of the agents of (a) or (b). 2. The method of claim 1, wherein the solid tumor that expresses EGF receptor is selected from the group consisting of squamous cell carcinoma, lung carcinoma, colon carcinoma, and glial cell tumors. 3. The method of claim 1, wherein the agent is the isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:11, 15 and 17-26, and fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1. 4. The method of claim 1, wherein the agent comprises a combination of the isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:11, 15 and 17-26, and fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1, and the monoclonal antibody that binds to the extracellular domain of EGF receptor. 5. The method of claim 1, wherein the agent is the isolated and glycosylated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:12, 38 and 27-36, and fragments thereof of about 80 to 419 contiguous residues in length, wherein the C-terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, and wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1. 6. The method of claim 1, wherein the agent is a combination of the isolated and glycosylated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:12, 38 and 27-36, and fragments thereof of about 80 to 419 contiguous residues in length, wherein the C-terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, and wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1, and the monoclonal antibody that binds to the extracellular domain of EGF receptor. 7. The method of claim 1, wherein the isolated polypeptide of (a) comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:11, 15 and 17-26. 8. The method of claim 1, wherein the isolated polypeptide of (b) comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:12, 38 and 27-36. 9. The method of claim 1, wherein the isolated polypeptide of (a) consists of an amino acid sequence selected from the group consisting of SEQ ID NOS:11, 15 and 17-26. 10. The method of claim 1, wherein the isolated polypeptide of (b) consists of an amino acid sequence selected from the group consisting of SEQ ID NOS:12, 38 and 27-36. 11. A method for treating a solid tumor characterized by expression of EGF receptor, comprising administering, to a subject in need thereof, an agent that binds to the extracellular domain of EGF receptor; wherein the agent comprises the amino acid sequence of SEQ ID NO:11. 12. A method for treating a solid tumor characterized by expression of EGF receptor, comprising administering, to a subject in need thereof, an agent that binds to the extracellular domain of EGF receptor, wherein the agent comprises the amino acid sequence of SEQ ID NO:12. 13. The method of claim 11, wherein the agent consists of the amino acid sequence of SEQ ID NO:11. 14. The method of claim 12, wherein the agent consists of the amino acid sequence of SEQ ID NO:12. 15. A method for treating a solid tumor characterized by expression of EGF receptor, comprising administering, to a subject in need thereof determined to have a tumor expressing the EGF receptor, an agent that binds to the extracellular domain of EGF receptor, wherein the agent is selected from the group consisting of (a) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1, or fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1, (b) an isolated and glycosylated polypeptide comprising the amino acid sequence of SEQ ID NO:2, or fragments thereof of about 80 to 419 contiguous residues in length, wherein the C-terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, and wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1, (c) a monoclonal antibody that binds to the extracellular domain of EGF receptor, and (d) combinations thereof, with the proviso that where the composition comprises the monoclonal antibody it also comprises at least one of the agents of (a) or (b). 16. The method of claim 15, wherein the solid tumor that expresses EGF receptor is selected from the group consisting of squamous cell carcinoma, lung carcinoma, colon carcinoma, and glial cell tumors. 17. The method of claim 15, wherein the agent is the isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO 1, and fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1. 18. The method of claim 15, wherein the agent comprises a combination of the isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, and fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1, and the monoclonal antibody that binds to the extracellular domain of EGF receptor. 19. The method of claim 15 wherein the agent is the isolated and glycosylated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, and fragments thereof of about 80 to 419 contiguous residues in length, wherein the C-terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, and wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1. 20. The method of claim 15, wherein the agent is a combination of the isolated and glycosylated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, and fragments thereof of about 80 to 419 contiguous residues in length, wherein the C-terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, and wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108 M-1, and the monoclonal antibody that binds to the extracellular domain of EGF receptor.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (42)
Plowman Gregory D. ; Culouscou Jean-Michel ; Shoyab Mohammed ; Siegall Clay B. ; Hellstrom Ingegerd ; Hellstrom Karl E., Antibodies to HER4, human receptor tyrosine kinase.
Cockerill George Stuart,GBX ; Carter Malcolm Clive,GBX ; Guntrip Stephen Barry,GBX ; Smith Kathryn Jane,GBX, Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
Carney Walter P. (North Andover MA) McKenzie Sara J. (Lynn MA), Detection and quantification of neu related proteins in the biological fluids of humans.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Greene Mark I. (Penn Valley PA) Dobashi Kunio (Gunma PA JPX) Davis James G. (Philadelphia PA) Hamuro Junji (Yokahama JPX), Ligand for the neu gene product.
Lippman Marc E. (Bethesda MD) Lupu Ruth (Gaithersburg MD), Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses.
Waterfield Michael D. (London GB2) Schlessinger J. (Rehovot CA ILX) Ullrich Axel (South San Francisco CA), Method of detecting truncated epidermal growth factor receptors.
Hudziak Robert M. (Corvallis OR) Shepard H. Michael (Rancho Santa Fe CA) Ullrich Axel (Portola Valley CA) Fendly Brian M. (Half Moon Bay CA), Monoclonal antibodies directed to the HER2 receptor.
Andya James ; Cleland Jeffrey L. ; Hsu Chung C. ; Lam Xanthe M. ; Overcashier David E. ; Shire Steven J. ; Yang Janet Yu-Feng ; Wu Sylvia Sau-Yan, Protein formulation.
Wels Winfried S. (Basel CHX) Hynes Nancy E. (Basel CHX) Harweth Ina-Maria (Grenzach-Wyhlen DEX) Groner Bernd (Basel CHX) Hardman Norman (Riehen CHX) Zwickl Markus (Basel CHX), Recombinant antibodies specific for a growth factor receptor.
Kluender Harold Clinton Eugene ; Benz Guenter Hans Heinz Herbert,DEX ; Brittelli David Ross ; Bullock William Harrison ; Combs Kerry Jeanne ; Dixon Brian Richard ; Schneider Stephan,DEX ; Wood Jill E, Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.